Cancer development is a complex process driven by inherited and acquired molecular and cellular alterations. Prevention is the holy grail of cancer elimination, but making this a reality will take a fundamental rethinking and deep understanding of premalignant biology. In this Perspective, we propose a large-scale concerted effort to create a Precancer Atlas (PCA), integrating multiomics and immunity -basic tenets of the neoplastic process. Study of the biology of neoplasia caused by germline mutations has led to new paradigm-changing therapy and precision prevention efforts, including immune interception and early detection research. Breakthrough advances include: studies of luminal progenitor biology in BRCA1-mutation carriers leading to an international breast cancer prevention trial, combinatorial chemoprevention efficacy in familial adenomatous polyposis (FAP), signal of benefit from imaging-based early detection research in individuals at high-germline risk for pancreatic neoplasia, and insights into the complex germline-somatic-immunity interaction landscape, e.g., germline APOBEC3A/ 3B-deletion allele confers predisposition to breast cancer, while surprisingly increasing somatic APOBECmutational burden and innate immunity to prevent infection. Cancer vaccine preventive activity in early mouse model and clinical precancer trials are building on the success of HPV vaccines. The increasingly complex cellular microenvironment (e.g., now including adipocytes, myocytes, neutrophils, fibroblasts, vascular and neuronal cells, microbiota, and even normal epithelial cells), interplay between defective DNA repair, mitophagy, mitochondrial dynamics, and ROS-dependent and TLR-induced inflammasome activation, and relationships between somatic copy number alterations (SCNA), mutations and immunity are all recent findings with major implications on malignant transformation and prevention. Next generation sequencing (NGS) studies discovered premalignant mutational accumulation in aging, established in clonal hematopoiesis, and cancer mutational signatures reflecting exogenous exposures or endogenous processes imprinted over time in precursors. Single-cell technologies are beginning to reveal vast molecular heterogeneity within precancers (e.g., in ductal carcinoma in situ [DCIS]and Barrett's esophagus) and will be needed to dissect the detailed cellular interactions within the neoplastic microenvironment. Preclinical models will allow controlled study of many emerging complexities in this field, including lineage-specific regulation of stem/progenitor cell fate. Accelerating the prevention of cancer will require a large-scale, longitudinal effort, leveraging diverse disciplines (from genetics and biochemistry to mathematics and engineering), initiatives, technologies, and models in developing an integrated multi-omics and immunity PCA -an immense national resource to interrogate, target and intercept events that drive oncogenesis.
Introduction
In early 2016, President Obama announced the creation of the National Cancer Moonshot initiative -a commitment to eradicate cancer by investing in greatly accelerating progress within diverse fields of cancer research, including prevention and early detection. Funding for this effort (and other cancer-related innovative research initiatives, e.g., stem cell research) was signed into law by the President in December 2016 as part of the 21st Century Cures Act (1) . Historically, the rate-limiting step for developing and implementing precision prevention approaches has been our limited understanding of precancer biology in contrast to the extensive study of advanced disease. For example, The Cancer Genome Atlas (TCGA), which includes volumes of omics data from >11,000 patients across 33 tumor types (including colorectal cancer [CRC] ), has transformed our understanding of cancer biology, identified hundreds of driver mutations that alter hallmark pathways, immense heterogeneity within and between tumors, and become a tremendous national resource for discovery, catalyzing the development of novel computational tools. In contrast, although the seminal multi-step, genetic model of carcinogenesis was defined in the colorectal adenoma-carcinoma sequence nearly 30 years ago (2) , limited numbers of adenomas have undergone deep sequencing (3) . The interaction between host immunity and neoplasia is now established as a fundamental principle of cancer development and progression. A diverse array of engineered models, single-cell technologies, and broad disciplines are beginning to be leveraged to probe early oncogenesis and malignant transformation. Large-scale longitudinal and systematic mapping is critical to develop an integrated omics and immune PCA, allowing dissection of the sequential molecular and cellular events that promote oncogenesis, to drive novel prevention and interception (4) (5) (6) (Fig. 1) .
Translating Inherited Risk into Precision Prevention
Germline cancer susceptibility
The genetics of various hereditary forms of cancer risk have been studied extensively and long been used to aid our understanding of sporadic neoplasia. Historically, most cancer susceptibility genes were identified through linkage studies in cancer families (7) . Furthermore, the biology of germline mutations in certain cancer genes (e.g., BRCA1 carriers) is much better understood than in the somatic setting and is now providing tremendous insight into personalized therapeutic and preventive strategies by leveraging the biology of the mutated gene itself. For example, study of the biology of tumors that develop in BRCA1/2-mutation carriers has led to paradigm-changing precision therapy with PARP inhibitors (8) , which have demonstrated preventive activity in BRCA1-deficient mice (9) . Similarly Lynch syndrome is serving as a model of immune oncology for sporadic MSI-H tumors (10, 11) . Furthermore, understanding the convergence of Wnt and EGFR signaling in FAP biology, characterized by germline APC mutations, led to a breakthrough trial of combination chemoprevention with erlotinib and sulindac, which An integrated multi-omics and immunity precancer atlas (PCA). Inherited and acquired molecular alterations and their interaction with the local microenvironment and immune system influence oncogenic progression to invasive carcinoma. Normal cells (light orange, far left) that have nuclear or mitochondrial germline mutations (green nuclei) acquire somatic alterations (dark orange), including due to viral infection (purple). These all can potentially alter the oncogenic state with loss of cell growth control, immune evasion and other hallmarks of cancer (7) , which can then result in the development of advanced precancers (multicolored cell mass with subclonal diversity/heterogeneity) that immediately precede invasive cancer (red). Molecular alterations, depicted by symbols in the nucleus, include mutations, SNPs, or epigenetic alterations. The accumulation of mutations (e.g., UV, ABOBEC) during life creates signatures (shown by the chromosomal insets and colored dots in gradient from cancer to normal). These mutational signatures, often identified in cancers, may predict early events, now extending to the precancer state (depicted by the orange/red cells with bold, yellow border). Multi-omic alterations interact (bidirectionally) with the complex tissue microenvironment, including the well-established immune cells (tumor-associated macrophages, MDSCs, NK and cytotoxic/regulatory T-cells) and more recently identified and less well understood cells in this context (e.g., adipocytes, myocytes, neutrophils, fibroblasts; and vascular, endothelial, neuronal, B-and other cells), microbiota and other cells/events to influence oncogenesis (see text). The continuum between immune state modulated by cytokines and growth factors includes immune surveillance, composed of the antigenic repertoire, adaptive and immune cells (upper left box), and immune suppression/escape (upper right box) along with the cells and markers that can lead to immune escape. Elucidation of the integrated multi-omics and immunity PCA will continue to evolve in complexity (e.g., recent SCNA/immune suppression finding), requiring continuous updating in this fast moving field.
successfully reduces duodenal neoplasia, the leading cause of cancer death following standard prophylactic colectomy for this devastating syndrome (12) . Multigene NGS is broadening the spectrum and complexity of cancer risk linked to various hereditary syndromes, frequently identifying individuals with high-penetrance germline mutations that are unexpected based on clinical history (e.g., CRC in BRCA1/2-and TP53-mutation carriers and breast cancer patients with Lynch syndrome) (13) (14) (15) . Furthermore, broad NGS identified germline mutations in cancer-predisposing genes in $10% of >1100 pediatric cancer patients, most of whom lack suggestive family histories of cancer (16) .
A fundamental question regarding inherited cancer susceptibility is why germline mutations in certain genes predispose to a particular spectrum of cancers. Although some genes have organspecific effects (e.g., mutations leading to hepatic overload which predispose to liver cancer), most cancer susceptibility genes have a broad range of functions (e.g., cell-cycle regulation). It is unclear, therefore, why different inherited DNA repair defects predispose to specific cancers (e.g., DNA mismatch repair [MMR] gene defects in Lynch syndrome to CRC and endometrial cancer; BRCA1/2 mutations [e.g., homologous recombination deficiency] to breast and ovarian cancer) rather than generalized systemic cancer risk, or why specific MMR and BRCA2 mutations are associated with different cancer patterns (17, 18) . For example, BRCA2 loss-offunction mutations confer increased risks of breast and ovarian cancer (but only small increases in prostate and pancreatic cancer), mutations in the central part of the gene confer higher risks of ovarian (vs. breast) cancer, and risks differ by context (e.g., family history, other modifying factors). Mouse models of Lynch syndrome have begun to unravel key mechanisms of the CRC predisposition by finding that butyrate, generated by gut microbiota from dietary carbohydrates, can act as an oncometabolite (19) . Interestingly, butyrate can have the opposite effects in different CRC models, likely reflecting different germline backgrounds, e.g., reduced dietary butyrate markedly decreased CRC development in MMR-deficient, but not MMR-proficient mice. Studies in APCMin/þ mice have found that celecoxib (a COX-2 inhibitor known to reduce intestinal adenoma burden) increased gut Coriobacteriaceae, which suppressed production of oncogenic metabolites (e.g., glycine and serine) (20) .
The mechanisms underlying the breast-specific predominance seen in BRCA1/2-mutation carriers are not clear but may be hormonally driven, with impaired local steroid-hormone regulation potentiating the BRCA1/2 mutagenic effect (21) . Defective ovarian hormone regulation and signaling, DNA repair, and BRCA cross talk in normal breast tissue from BRCA1-mutation carriers may also contribute to neoplasia at this site (22) . BRCA1-haploinsufficient non-cancer cells have differences in gene dosage, DNA damage repair, and lineage commitment that have begun to shed light on tissue specificity (23) ; mutations in a single BRCA1 allele are sufficient to alter non-neoplastic breast epithelial and mammary progenitor cells. Direct cell-type comparisons showed that DNA damage response, genomic instability, telomere erosion, and premature senescence are all increased in primary breast epithelial (but not fibroblast) cells with BRCA1-haploinsufficiency. BRCA mutations have been shown to induce perturbations in telomere-telomerase system, which contribute to neoplasia, based mainly on data from cancer cells. Recent studies extended this work to BRCA1-silenced nonmalignant breast epithelial cells and revealed profound alterations in telomere homeostasis, involving decreased DNMT1 levels and TIN2 telomere binding and increased telomere trimming, shortening of single-stranded overhang, telomere length heterogeneity, and loss on chromosomal ends (24) . Exposure to estrogen is central to breast cancer development; therefore, the identification of ER-a as a putative BRCA1/BARD1 ubiquitination substrate reveals a potential link between loss of this ubiquitin ligase activity and breast cancer (25) . We have only recently begun to uncover the earliest steps of BRCA1-mutant breast neoplasia. Regulators of mammary epithelial cell identity are crucial to cell fate determination and switching, and manipulation of mammary lineage regulators can affect progenitor cell fate decisions, placing premalignant cells on a path towards specific cancer phenotypes. In the case of BRCA1-mutation carriers, aberrant expression of the transcription factor Slug was shown to be a cause for cell fate switching. Identifying additional epigenetic and transcriptional regulators of cell fate and linage transitioning will provide deeper insight into this complex process and interception targets (26) .
Fanconi Anemia (FA), a rare hereditary syndrome related to BRCA1/2-mutation carriers, involves 19 genes (including BRCA2/ FANCD1 and BRCA1/FANCS) and is characterized by a genetic defect in double-strand DNA repair pathway. FANCC and certain other FA pathway genes are linked to host innate anti-viral immunity. Heterogeneous immune defects, including B-cell dysfunction, may account for susceptibility to HPV (and other viral) infections and variable immune responses to HPV vaccines, which has implications for preventive cancer vaccine development. Recent study elucidated the mechanistic interplay of defective mitophagy, mitochondrial dynamics, and ROS-dependent and TLR-induced inflammasome activation mediating IL-1b secretion (27) . Somatic mutations or epigenetic silencing of FA genes is common in sporadic breast, ovary, and pancreatic cancer. Failure to remove damaged mitochondria can lead to increased mt-ROS, genotoxic stress and tumorigenesis in FA, and sporadic setting with somatic FA driver mutations (28) .
While the majority of breast cancers arising in BRCA2-mutation carriers are ER positive, most BRCA1 breast cancers are ER negative at diagnosis. Large randomized controlled trials of tamoxifen and other anti-estrogens consistently show preventive benefit confined to ER-positive breast cancer, although observational studies suggest that tamoxifen can reduce breast cancer risk, especially contralateral breast cancer, in BRCA1-mutation carriers (29) . Potential mechanisms for the latter include: BRCA1 carriers have augmented estrogenic signals (21) , breast cancer risk associated with SNPs located near ESR1 (which encodes ERa) (30) and estrogen and anti-estrogen (including tamoxifen) effects on proliferation in normal breast epithelial tissue from BRCA1 carriers, similar to non-carriers at increased risk and population risk of breast cancer (31) . Brca1 loss with estrogen signaling promotes tumor development in mice (32) . Estrogen controls the survival of BRCA1-deficient mammary epithelial cells via a PI3K-NRF2-regulated pathway (33) . Estrogen depletion also augments innate and adaptive immunity (34), e.g., by decreasing mobilization and immunosuppressive activity of myeloid-derived suppressor cells (MDSC) (35, 36) . These and other studies indicate important estrogen/hormonal effects in early ontogeny. Indeed, BRCA1-mutant mammary stem and progenitor cells (which lack ERa and PR) appear to be indirectly activated by steroid hormones via paracrine signaling mediated by RANK ligand (RANKL), which is reduced by tamoxifen (36), see below.
Elegant studies of luminal progenitor biology (37, 38) have led to a transformative potential to prevent/delay BRCA1-associated breast cancer, a disease for which the best current preventive option is prophylactic surgery. A highly proliferative subset of luminal progenitor cells that give rise to basal-like breast cancer, constitutively express RANK and are hyper-responsive to RANK-L, a key mediator of progestin-driven mammary carcinogenesis. Furthermore, RANKþ BRCA1-deficient/mutant progenitor cells are more susceptible to DNA damage and aberrant downstream NFkB activation than RANK-mammary progenitor cells (39) . Pharmacologic RANK-L inhibition or RANK deletion (in mammary epithelium) in several GEMMs markedly inhibits Brca1-driven mammary tumorigenesis (37, 38) . High-level RANK-L drives epithelial-mesenchymal transition with invasion and correlates with high-grade ER/PR negative disease and mammary stem cell number (in young breast cancer patients) (40) . RANK-L/ RANK signaling (41) also can influence innate and adaptive immunity (42, 43) . RANK-L produced by regulatory T-cells (Treg) promotes mammary cancer and T-cell tolerance to intestinal bacteria (43) . Finally, NFkB hyperactivation in BRCA-mutant breast cancer cells appears to be associated with an immune signature (36) . Recently, a second RANK-L receptor, LGR4, has been implicated in the regulation of multiple developmental pathways (44) . Serum levels of osteoprotegerin, the endogenous RANK-L inhibitor, are significantly lower in BRCA1 carriers (vs. controls), premenopausal women, and are inversely associated with breast cancer risk (45, 46) . Certain SNPs in the TNFRSF11A locus have been associated with increased RANK expression and breast cancer risk in BRCA1 carriers (38) . Denosumab (a RANK-L mAb inhibitor FDA-approved in 2010 with a well-established safety record for treating osteoporosis and bone metastases, espousing both efficacy and toxicity superior to biphosphonates (47)) blocked progesterone-induced proliferation in BRCA1-mutant organoids and reduced breast epithelial cell proliferation and progenitor cell clonogenic potential in small pilot window studies of BRCA1 carriers (37, 38) . Theoretically, RANK-L inhibition would work best to prevent/delay tumor onset for premenopausal BRCA1-mutation carriers based on the above science and recent data finding risk-reducing salpingo-oophorectomy to be ineffective in this setting (48) . Based on these data, denosumab is in late-stage development for a large-scale international breast cancer prevention trial in BRCA-mutation carriers (37, 38) .
The first real benefit of early detection research in pancreatic cancer, imaging people with high-penetrance mutations, was recently reported (49) . Unselected patients may have a very high (>15% in one clinic-based cohort) prevalence of germline mutations (particularly of BRCA1/2 and among Ashkenazi Jewish individuals) (50) . Precursor lesions in people with high-penetrance germline mutations have a higher malignant potential (than other pancreas high-risk groups) (51, 52) -leading some centers to recommend germline testing for all new pancreatic cancer patients. Precedent for such an approach already exists in NCCN guidelines for ovarian cancer, where a substantial fraction of unselected patients will carry BRCA1/2 mutations (most without consistent clinical/family histories) and screening has limited benefit (53) . The development of molecular imaging techniques to detect high-grade lesions (PanIN-3) may further improve prevention and early detection of this fatal disease (54) .
Immunologic mechanisms, including cancer vaccines, may also be key to realizing precision prevention in certain types of neoplasia characterized by immunogenic antigen production, as seen in various inherited settings ( Table 1 ). Cancers that arise in Lynch syndrome with inherited DNA MMR gene defects display a high-level of microsatellite instability (MSI-H) and widespread accumulation of somatic frameshift mutations/neoantigens (55), thought to underlie the success of immune checkpoint inhibitors in this setting (10, 11) . These breakthrough advances in immunotherapy along with early immunosurveillance (T-cells specific to MSI-related neoantigens (56)) in "healthy" Lynch syndrome carriers have generated interest in developing preventive cancer vaccines targeting predictable frame-shift mutationderived peptides.
Universal CRC tumor testing for MMR deficiency to screen for Lynch syndrome, a paradigm-changing approach for identifying inherited cancer risk, has become standard practice for all newly diagnosed CRCs and is now being extended to endometrial cancers (57) . This benefits both the patient and at-risk family members for intensive and early screening and aspirin or potentially other NSAID prevention (58, 59) . The profound activity of immune checkpoint blockade in MMR deficient tumors (11) has added to the enthusiasm of this universal screening approach. This tumor testing approach is under study in lung cancer patients: the $1% with tumor EGFR T790M mutation at diagnosis have a high risk of carrying germline T790M mutations (60) . Large-scale pan-TCGA analysis of tumor sequencing data (>4,000 tumors, 12 cancer types) revealed rare germline mutations (e.g., BRCA1/2, FANCM, MSH6) in 4-19% of cancer types, unselected for family history and associated with increased somatic mutation frequencies (61) . Germline variants and somatic events are also intricately linked, including specific haplotypes with JAK2 V617F in myeloproliferative neoplasms (62) and EGFR exon 19 microdeletions in non-small cell lung cancer (63) . Germline variation was also found to influence gene expression in breast cancer risk loci (64) . Recent large-scale approach (22 tumor types, 5954 tumors) integrated common genotypes (412 germline loci) with somatic changes to obtain a pan-cancer view of how inherited variation can influence oncogenesis. Translating genome-wide association studies (GWAS) to the clinic has been challenged by the generally small effect sizes of risk variants (see below). This genome-wide analysis of germline-somatic interactions among cancer patients identified common germline alleles that had very large effects on somatic events. Novel associations included a 15q22.2 allele with >10-fold increased somatic alteration of GNAQ and an intronic SNP in RBFOX1 with >8-fold increase in mutation rate of SF3B1 affecting RNA splicing. Interestingly, some frequently altered high-penetrance cancer genes (e.g., TP53 and PIK3CA) were not found to be influenced by common germline variants. For genes near the median mutation frequency, such as BRCA1, which is altered in $3% of tumors, the study was powered to detect changes in mutation rate of !3.0-fold. This study found that genetic background can influence the somatic evolution of a tumor by directing where (organ site) and how (which genes are impacted transcriptionally) cancer develops -making it possible to anticipate and intercept key early events during tumor development (65) . As broad NGS of blood and neoplasias become more widely used and germline-somatic relationships comprehensively mapped, shared and distinct germline and/or somatic events can be integrated into the PCA and exploited as prevention targets (17, (66) (67) (68) .
GWAS have contributed to expanding catalogs of implicated genes and pathways for many complex human diseases and are beginning to shed light on shared and unique etiological and pathological disease components. Combining large-scale GWAS findings across cancer types (breast, ovarian, and prostate) and using fine-mapping pathway analysis and polygenic risk scores (PRS) discovered cross-cancer risk loci has the potential to shed light on shared biology underlying these hormone-related cancers (69) . Only a few SNPs are within known cancer predisposition genes (e.g., ATM and TP53 carriers), and none are associated with cancers that occur in carriers of rare, penetrant mutations. While the low penetrance of most GWAS loci has limited clinical translation, the combined effects of such SNPs to create robust PRS (70) may be more useful clinically, especially, for example, as modifiers of high-risk BRCA1 and BRCA2-mutation carriers given that even small relative risk changes translate into large absolute effects. Most general population breast cancer SNPs are associated with ER-negative or -positive disease and, respectively, in BRCA1-or BRCA2-mutation carriers. Similarly, only general population loci (e.g., 19p13.11) associated with high-grade serous ovarian cancer modify risk of ovarian cancer in BRCA1-and BRCA2-mutation carriers, where tumors are of this high-grade subtype (71) . The importance of post-GWAS functional studies in this context is illustrated by finding a SNP in the OGG1 glycosidase gene of the Base Excision Repair pathway, associated with increased ovarian cancer risk in BRCA1-mutation carriers, possibly due to OGG1 transcriptional down regulation, telomere shortening, and genome instability. These results provide insight into BRCA1 mutation mechanism and prevention (72) . The new OncoArray approach to study genetic architecture of common cancers, which includes dense mapping of loci associated with single or multiple cancers, pleotropic effects and cancer related traits, will also build on first-generation GWAS findings (73) . Finally, the ability of GWAS to discover novel cancer genes/pathways underlying the observed risk is now being exploited for future drug development or repositioning, aided by studies in relevant preclinical models. These GWAS-initiated efforts have already led to preventionrelevant drug targets, including IL-17 and ESR1 (70, 74, 75) .
A key challenge is that many GWAS-identified loci are not near known coding or regulatory regions, leaving associated mechanisms and functions unclear. Linking susceptibility variants to their respective causative genes and cell-specific regulatory elements thus remains a high priority in order to realize the full potential of association studies. A rigorous integrated approach to this issue recently confirmed the widespread genetic regulation of immune and inflammatory pathways, including in CRC precursors (76) . High-resolution genetic, epigenetic, transcriptomic, and RNA splicing studies, provided powerful approaches to annotate the putative consequence of disease associations. These integrated investigations were extended to primary human cells in diseaserelevant contexts to unravel the cell-and context-specific regulatory effects of complex disease variants. This deep characterization of transcriptional regulation of molecular events will greatly advance functional studies of human disease variants, identifying novel disease mechanisms and prevention opportunities. Certain SNPs underlying cancer risk are linked to hypermutability and immune activation (77) (78) (79) and intestinal barrier function (discussed below). For example, a germline APOBEC3A/3B-deletion allele confers breast cancer risk via increased APOBEC-dependent mutational processes. Great variation in population frequency of this deletion allele suggests selection for it. Some APOBECs are involved in innate immunity to infection possibly conferred by this deletion allele, suggesting strikingly disparate effects of APOBEC mutagenesis on infection and cancer 80).
Mitochondrial biology and genetics in cancer predisposition
Mitochondrial DNA (mtDNA) with its mutations and polymorphisms is a relatively underappreciated field in cancer research. Human mtDNA is maternally inherited (and mapped initially from Africa) (81) and encodes 37 genes: 22 transfer RNAs, 2 ribosomal RNAs and 13 protein subunits of the electron transport chain (ETC) complexes and ATP synthase (mtOXPHOS proteins), essential for respiration. There are several mtDNA copies per mitochondrion and hundreds of mitochondria per cell (82) . Generally, neoplastic cells possess functional mitochondria and retain the ability to conduct oxidative phosphorylation. In fact, targeted depletion of mitochondrial DNA can reduce tumorigenic potential in vivo (83) . While it has long been known that somatic mtDNA alterations are frequently acquired during (81) . mtDNA has a very high mutation rate, greater than an order of magnitude higher than the nuclear genome. Furthermore, mtDNA genes are intimately linked with $2000 nuclear genes encoding proteins that function within mitochondria, which can produce Mendelian patterns of inheritance. Inherited deleterious missense alterations in mtDNA genes, such as ND6 and COI (cytochrome oxidase subunit I), which code for subunits of OXPHOS complexes I and IV, have been associated with risks of various cancers. Inherited mutations in the COI gene (associated with increased ROS production, which contributes to tumorigenesis) are associated with prostate cancer risk (somatic COI mutations are also found in prostate cancer), and may explain increased risks in African American men; certain African mtDNA lineages harbor COI gene variants that may contribute to risk of other cancers among African Americans (85, 86) . mtDNA variants have been associated with risks of ovarian (87), bladder (88), breast (89), endometrial (90), and HPV-infection and cervical cancers (91), among others. The progression of nonalcoholic fatty liver disease to nonalcoholic steatohepatitis (NASH), which predisposes to hepatocellular carcinoma, has been shown to be associated with a mtDNA SNP in the mt-Atp8 gene (a subunit of OXPHOS complex V, ATP synthase). This variant has profound effects on hepatic lipid and acylcarnitine metabolism and susceptibility to high-fat dietinduced NASH (92) . Generating animal models of these and other inherited mtDNA mutations (93, 94) will be critical to probing the contribution of mitochondrial biology to inherited cancer risk. Deleterious alterations in mtDNA are inherently heteroplasmic (harboring a mixture of mutant and wild-type mtDNA) with high levels of these severe mutations being lethal. Since mtDNA transmission during mitosis is the result of stochastic distribution into daughter cells, milder mtDNA polymorphisms can shift to become predominantly enriched within individual cells and closer to pure mutant (homoplasmy), potentially contributing to neoplastic transformation. The importance of this phenomenon for cancer predisposition has been demonstrated in a pedigree in which a mtDNA complex I ND5 m.12425delA frameshift mutation is present in homoplasmy in a nasopharyngeal oncocytic tumor, which was inherited as a germline mutation, transmitted at lower heteroplasmy levels (5-10% mutant), and thus masked by wild-type mtDNAs. Shift to homoplasmic ND5 mutation occurred exclusively in tumor cells and correlated with lack of the ND6 subunit, indicating that complex I mutations may have a selective advantage. Thus, while the transmission of the mutant mtDNA in this pedigree was phenotypically silent, the chance increase of the mutant mtDNA in somatic cells caused oncocytic transformation (95) . In contrast to Mendelian genetics, the heteroplasmic mtDNA genotype is continuously changing during successive cytokinesis to generate cells with varying oncogenic potential (86, 96) . Widespread heterogeneity has been reported in the mtDNA of normal human cells and heteroplasmic variants among different tissues within the same individual, highlighting the existence of complex mixtures of related genotypes rather than a single genotype. Mechanistic study of the regulation of mtDNA heteroplasmy may yield novel prevention insights. Because of its high mutation rate, mtDNA is highly polymorphic, harboring functional variants that can be beneficial or deleterious depending on context. A subset of mtDNA variants cause subtle changes in OXPHOS, which in turn could modulate a wide range of contextdependent cellular functions of adaptive relevance, including inflammation, stress, autophagy, and oncogenic responses to diet and other factors (97, 98) . Those functional mtDNA variants that were beneficial (adaptive) in a particular environment increased in number and gave rise to descendant mtDNAs, which share the founders' beneficial variant. Migration (or other major changes in diet, stress, etc.) can make previously adaptive variants become maladaptive and predisposed to a wide range of common diseases (81) .
A recent murine study highlighted the importance of mtDNA in tumorigenesis by examining PyMT transgenic mice (which are inherently predisposed to developing mammary tumors) with identical nuclear genomes and found that varying the mtDNA genetic background of these mice influenced both mammary tumor latency and progression (99) . In normal mice, the mitochondrial-targeted catalase transgene (mtCAT) reduces somatic mtDNA mutations (100) and, when crossed with PyMT mice, the incidence of mammary cancer is greatly reduced (101) . Mechanistic studies have demonstrated the profound influence of subtle changes in mtDNA haplotype/variation on obesity and aging, both of which are key cancer risk factors (102) . Emerging data also suggest a complex communication between the nucleus-cytosol and mitochondria (103) . Murine models with germline mutations in the nuclear gene SUV3, which encodes for a mtRNA helicase, are characterized by marked somatic mtDNA instability, hypermutability, shortened lifespan, and various cancers -a unique model to study mitochondrial genomic instability in cancer predisposition. Clinical relevance was shown by reduced SUV3 expression in two independent cohorts of human breast cancer (104) . Mutations in nuclear DNA genes influencing transformation involve some of the same targets/mechanisms affected by mtDNA, including TETs, succinate, fumarate, NRF2, and a-ketoglutarate dioxygenases (105, 106) -all important in cancer risk.
Mitochondria may also be intimately involved with T-cell immune surveillance, since T-effector cells are more glycolytic while Treg cells are more oxidative. Within neoplastic cells, glucose is converted to lactate (which promotes inflammation, angiogenesis and tumorigenesis), thus inhibiting T-effector function. Treg function is enhanced, which further inhibits the Teffector cells, and suggests that immune rejection of neoplasia might be enhanced in this setting by mild complex I inhibitors such as metformin, whose effectiveness should be increased in neoplastic cells with partial OXPHOS dysfunction (107, 108) . Mitochondria can also influence the inflammasome, innate immunity, IL-1b and NFkB inflammatory pathways (109, 110) . BRCA1 has been observed within mitochondria, suggesting a role in repair of mtDNA and raising speculation that germline BRCA1 mutations reprogram breast metabolism towards mitochondrialdependent biosynthesis and oncogenesis. Metformin can also prevent BRCA1 haploinsufficiency-driven oncogenesis by: restriction ("starvation") of mitochondrial-dependent biosynthetic intermediates (111); regulating mitochondrial-nuclear communication; and modulating epigenetics (targeting histone acetylation) in genomically unstable precancers (112) to guide metabolomic-epigenetic prevention strategies. As with nuclear GWAS, certain mtDNA alterations modify (lower) risks of breast cancer in germline BRCA2 mutations (113) . Future GWAS integrating both nuclear and mitochondrial studies will provide a more comprehensive germline landscape, including somatic interactions.
Big Genomics Data of Premalignant Somatic Tissues
The collection and analyses of NGS big data are beginning to provide biological insights into cancer prevention and early detection in the context of studies characterizing somatic genomic alterations. It is worth noting that, in addition to comprehensive analyses of "big genomics data," several recent studies that have also examined cancer microbiomes (reviewed in (97, (114) (115) (116) ), transcriptomes (117) (118) (119) and epigenomes (reviewed in (120, 121) ). In addition to big data generated from somatic sequencing efforts, GWAS has involved over one million cancer patients worldwide across most organ sites identifying $3000 cancer-related genetic associations (122, 123) and has been studied in some precancers such as Barrett's esophagus (124) (125) (126) , colorectal adenomas (127), DCIS (128) and hematologic premalignancies (below).
The genome of a malignancy can be examined as an archeological record bearing the cumulative imprints of all mutational processes that have been operative throughout the cellular lineage between the fertilized egg and cancer (129) . Each mutational process leaves a characteristic imprint, termed mutational signature, which can change over time, and almost all mutational signatures detected in a cancer genome have been imprinted during the precursor phase of a cancer cell (129) . Examination of the cancer genomes from >12,000 patients has revealed more than 30 distinct mutational signatures (129, 130) , including those related to environmental exposures, such as UV-light, aflatoxin, and tobacco (cancer.sanger.ac.uk/cosmic/signatures). Some of these signatures have already been used for identifying the presence of specific carcinogens, including aristolochic acid (131), one of the most potent known human carcinogens -a chemical present in certain plants still in use even today especially in China -with global public health risks of urologic and hepatic cancers (132) (133) (134) . It will be important for the PCA to study both premalignant and normal-aged tissues with the goal of identifying relevant mutational signatures that may provide important clues into premalignant oncogenesis, prevention, and interception. However, it is important to note that approximately half of the currently known cancer signatures have unknown etiology and ongoing efforts have started exposing experimental systems to known carcinogens in an attempt to reproduce/identify them (135, 136) .
Another set of widespread and extensively studied endogenous mutational signatures are those attributed to ectopic activity of the APOBEC family of deaminases (130, 137) . Recent examination across more than 10,000 specimens from 36 distinct cancer types revealed that these signatures are found in more than 30% of cancer samples and account for approximately 15% of all somatic mutations across these cancers. The activity of these APOBEC mutational signatures is especially strong in bladder and cervical cancer where they account for more than 75% of all somatic mutations in each of these cancer types (137) . In cancers of the cervix and oropharynx, these APOBEC mutational signatures are predominately triggered early by HPV infection (137, 138) , and it has been speculated that APOBEC mutational signatures are imprinted during the preinvasive phases of these cancers (137, 138) . In contrast, APOBEC signatures are believed to be late events in lung and many other cancer types, and are found in subclonal expansions and intratumor heterogeneity (139) . Germline variants can affect endogenous mutational signatures such as the APOBEC3 germline copy number polymorphism discussed above associated with APOBEC-dependent mutational burden in breast cancer (80) . Germline variants can also influence exogenous mutational signatures due to environmental exposures. For example, disruptive germline polymorphisms in MC1R, contributor to phosphorylation of DNA repair proteins, have been associated with increased somatic mutation burden due to a UV light-related mutational signature and a higher risk for developing skin cancer (140) .
Multiple mutational signatures reflect failure of different DNA repair pathways. A specific mutational signature associated with both germline and somatic BRCA1 or 2 mutations (130) has been observed in breast, ovarian, pancreatic, gastric, and esophageal cancers (even those without BRCA1 or 2 mutations) (141) (142) (143) (144) (145) (146) , associated with markers of immunity in subsets of the former three cancers (147) , suggesting a potential role for immune-based prevention against such cancers. A mutational signature reflecting the accumulation of unrepaired reactive oxygen species, mainly 8-oxoguanine, has been identified in CRC and adenomas arising in individuals with pathogenic germline MUTYH mutations, which cause base excision repair (BER) defects (148) . Additionally, a failure of transcription-coupled nucleotide excision repair (NER) due to somatic mutations in ERCC2 in bladder (including preinvasive) neoplasia has been shown to exhibit a specific mutational signature (149) . Germline defects in other NER genes can cause Xeroderma pigmentosum, a rare autosomal-recessive genetic disorder associated with high risk of UV-associated skin cancer due to faster accumulation of UV-associated DNA damage and mutational signatures (150) . UV-induced nonmelanoma lesions can be reduced using bacterial DNA repair enzymes (151) or nicotinamide, which can prevent UV-induced immune suppression and enhance DNA repair (152) .
In addition to mutational signatures related to the failure of DNA repair mechanisms and ones due to endogenous/exogenous exposures, large-scale genomics studies have also identified mutational signatures responsible for the unavoidable background mutation rate in somatic cells. Notably, two unrelated mutational signatures have been found to act as endogenous mutational "clocks," characterized by accumulating somatic mutations within all normal somatic cells of the human body with the progression of age (153, 154) . One of these mutational signatures has been attributed to spontaneous deamination of 5-methylcytosine in the context of CpG (its rate of "ticking" appears to be influenced by cellular division), while the etiology of the second clock-like signature remains unknown. Interestingly, a recent study demonstrated the increased rate of one mutational clock to be mechanistically linked to tobacco smoking (149, 155) . The somatic mutation loads in single-cell lineages provide information about an individual's lifetime history of mutagenic exposure and the impact of intrinsic factors on mutagenesis. Expanding this study to precancers, more cell types and larger populations in the PCA would further refine estimates of the rates of somatic changes in human genomes. Understanding the contributions of environmental and endogenous mutagenic processes to somatic mutation loads is fundamental to develop preventive strategies (156) .
Analyses of omics data from precancers are beginning to emerge. Despite the relatively small sample sizes within such analyses, cross-sectional, precancer/cancer pair studies suggest that many precancers share genomic alterations with their respective invasive cancers, including ductal and lobular breast cancer (157, 158) , pancreas (159), non-melanoma skin (160, 161) , melanoma (162) , lung adenocarcinoma (163) and colorectal neoplasia (148) . From an NGS, genomics, transcriptomics (see below) and big data perspective, Barrett's esophagus is the beststudied epithelial precancer (141, (164) (165) (166) (167) , including three GWAS (125, 126, 168) and a post-GWAS analysis reporting some CDKN2A SNPs associated with reduced esophageal cancer risk (169) . Somatic tissue studies of Barrett's esophagus/esophageal cancer pairs revealed that the overall mutation rate (single-nucleotide variations) was lower in Barrett's esophagus than esophageal cancer but higher than that of several invasive cancers (e.g., breast cancer, multiple myeloma [MM]) and most recurrently mutated genes in esophageal cancer were remarkably similar to the matched Barrett's esophagus. Only mutations in the tumor suppressors TP53 and SMAD4 were associated with advanced/ invasive neoplasia, low or absent from Barrett's esophagus (166) , and that intra-tumor genomic heterogeneity, with some contribution of aberrant methylation, seemed to drive neoplastic progression. See longitudinal section below for Barrett's esophagus SCNA studies.
Two recent large-scale NGS studies of mtDNA in cancer (>2,000 human cancer specimens, 30 tumor types) identified a mutational signature with unique heavy strand-specific C > T transition. More importantly, this missense mutational signature was considered neutral (analogous to passenger mutations in nuclear DNA), not compromising mitochondrial function (170) . One of these studies further refined the mtDNA mutational map with matched transcriptome sequencing (RNA-seq) data (171) . Although DNA/RNA allelic ratios generally were consistent, some mutations in mt-tRNAs displayed strong allelic imbalances caused by accumulation of unprocessed tRNA precursors, indicative of impaired tRNA folding and maturation, which underlie a range of diseases. Both studies found a selective pressure against deleterious coding mutations affecting oxidative phosphorylation, indicating that tumors require functional mitochondria. Unexpectedly, known dominant mutagens, such as cigarette smoke or UV light, had a negligible effect on mtDNA mutations. Another new study has reported significant correlations between mtRNASeq and mtDNA copy number, with some important exceptions (e.g. MT-ND5 and MT-ND6) (172) . mtDNA mutations are frequent in Barrett's esophagus without dysplasia (173) and have been used to characterize genetic lineages that assess clonal relationships, e.g., between Barrett's esophagus and esophageal squamous cells (174) . Clonal expansion of mtDNA mutations can result in mitochondrial dysfunction, such as decreased ETC enzyme activity and impaired cellular respiration. NGS of mtDNA of oncocytomas, which are rare benign tumors of epithelial cells defined by excessive amounts of mitochondria, has identified a pathogenic mutation signature that compromises the overall function of the mitochondria, proposed to serve as a metabolic barrier for these benign tumors, and perhaps precancers, progressing to malignancy (175) .
In addition to the studies above, a systematic approach to classify cancers using transcription profiles at both bulk tumors and single-cell resolution has been described (176-179). These profiles not only provide molecular bases for classifying cancers with shared transcriptional programs across different cancer types but also characterize heterogeneity that exists within individual neoplasias (180) . Whole transcriptome profiling using RNAseq, pathway enrichment, and functional assays of BE found novel cell-cell communication, with normal epithelial cells sensing and dramatically suppress dysplastic cell behavior (e.g., motility, signaling pathways). These effects are distinct from the stromal and immune cell microenvironment effects. Downregulated TGFB, EGF, and Wnt pathways associated with the differential transcriptional profiles observed in the dysplastic cells in coculture (normal and dysplastic Barrett's epithelial cells, which often co-exist in vivo) (167) . Single-cell approaches would allow analysis of different subpopulations of cells, including highly variable epithelial cell motility and immune, stromal, and other microenvironment cellular components surrounding the neoplasias (Figure 1) (167, 179) . Furthermore, oncogenic pathways and developmental-and immune-based gene expression signatures can be used for "pathway/phenotype"-based molecular characterization (181) (182) (183) .
Recently, a novel analytic approach to define oncogenic states and produce functional maps of cancer has been established. This serves as a framework for combining experimental and computational strategies to deconvolve oncogenic pathways/ signatures derived from oncogene activation into transcriptional components that can be used to determine oncogenic states. By mapping precancers and cancers onto distinct oncogenic states, the resulting functional map can be used to characterize how these states relate to various omics features, including NGS mutations, copy number alterations, gene and protein expression, gene dependencies, and biological phenotypes; and to predict which interventions are more likely to have a significant effect (184) . This approach has been used to effectively map cancers with altered KRAS/MAPK pathways into divergent functional states. Studies in pancreatic oncogenesis highlight the need for big data approaches to interpret neoplastic complexity, including KRAS mutation subtypes and Hippo pathway interactions, profound effects on cell metabolism, DNA repair, immunity, mitochondrial biology, and distinct precursor pathways (185) . Mutant Kras in pancreatic acinar cells induces expression of ICAM-1 to attract macrophages and drive PanIN development: direct early cooperative mechanisms between driver mutations and inflammatory environments (186) . Even B-cells can initiate and promote pancreatic tumorigenesis. For example, primary human and mouse models found B-cell infiltration in proximity of PanIN lesions, due to stromal secretion of the B-cell chemoattractant CXCL13 (187) . Another study found highly expressed HIF1a in PanINs; deletion of HIF1a increased secretion of CXCL13 and related attractants and accelerated malignant transformation. Depletion of B-cells reduced PanIN progression (188) . These dynamic maps can continually integrate new data, be generalized to consider gene networks and interactions (189) , including the germline, and study the close interchange with the immune microenvironment. Integrating functional genomics data, such as those described above, to the maps of oncogenic states will provide further insight into the cellular contexts in which genomic alterations contribute to malignant transformation (190) .
Epigenetics
Previous work has yielded only a limited big data perspective of the neoplastic epigenome, primarily in hematologic neoplasia, where chromatin modifiers are in general among the most Perspective Cancer Res; 77(7) April 1, 2017
Cancer Researchfrequently mutated in cancer (121, 191) . Most studies have focused on performing functional analysis on a few genes in a limited number of samples as reviewed below. Widespread epigenetic field defects have been observed in apparently normal breast tissue located adjacent to breast cancer (192) and also associated with inflammation-related cancers, such as H. pyloriinduced neoplasia, in which NGS has revealed more cancer pathway-related genes affected by DNA methylation than by genetic alterations (193) . The ten eleven translocation (TET) enzymes oxidize 5-methylcytosines (5mCs) and promote locus-specific reversal of DNA methylation (194) . An epigenetic mitotic clock was developed using a novel mathematical approach. A key feature underlying the construction of this clock is the focus on Polycomb group target promoter CpGs, which are unmethylated in many different fetal tissue types, thus allowing defining a proper ground state from which to then assess deviations in aged tissue. By correlating the tick rate predictions of this model to the rate of stem cell divisions in normal tissue, as well as to an mRNA expression-based mitotic index in cancer tissue, this model approximates a mitotic-like clock. The epigenetic mitotic clock-like signature exhibits a consistent, universal pattern of acceleration in cancer in normal epithelial cells exposed to a major carcinogen. Epigenetic clonal mosaicism is maximal before cancer emerges. Unlike the mutational clock-like signatures discussed above, this epigenetic clock is based on clinical DCIS and lung CIS progression to cancer and normal at-risk tissue; a concrete example of a molecular mitotic-like clock that predicts universal acceleration in precancer (195) . Smoking was associated with an increased rate of this mutational clock. Another approach to intratumoral heterogeneity analyzed DNA methylation patterns at two genomic loci that were assumed to have no role in gene regulation, in contrast to driver methylation changes. Methylation at such neutral loci were unlikely to be under selective pressure and therefore, could serve as a``molecular clock'' to measure mitotic divisions based on the higher error rate of DNA methylation maintenance relative to the error rate of DNA polymerase (196) .
Aberrations of the epigenetic modulator TET2 are among the first alterations identified in several hematologic premalignancies. The TET family of proteins was originally named due to the TET1 fusion partner in mixed-lineage leukemia (MLL)-rearranged AML (see "biochemistry" subsection below), however, this translocation is rare, and its significance in leukemogenesis is unclear. In contrast, TET2 mutations are found in premalignant hematopoietic stem cells (HSCs), including of myeloproliferative neoplasms (MPNs) and MDS, and are frequently observed in aged healthy individuals (197) with propensity to transform (see clonal hematopoiesis below). Disruption of TET2 in mouse models increases HSC proliferation and clonal expansion, prone to additional oncogenic events generally required for malignant transformation (194) . Mouse models found that co-occurring Tet2 disruption with Asxl, Ezh2, or Jak2 V617F results in MDS or MPN. Recurrent dominant point mutations in IDH1 and IDH2 are early events in some hematologic neoplasias that lead to loss of TET activity and other epigenetic changes (198, 199) . In addition, TET2, IDH1, and IDH2 mutations are frequently observed in lymphoma precursors (200) (201) (202) , and the frequency of TET loss-of-function (which drives hematologic transformation) in these settings supports testing TET activators. TET modulators (203) , can enhance antigen presentation, increase IL-6 production by macrophages (204) , affect Tregs (205) , and alter expression of endogenous retroviruses, cancer testis antigens, and stem cell antigens in premalignant lesions resulting in enhanced immunogenicity (206) .
Another epigenetic mechanism found to be important in premalignant biology involves RNA editing by ADAR enzymes, which results in adenosine-to-inosine conversion of RNA thereby inducing virtual adenosine-to-guanine mutations (since inosine bears molecular resemblance to guanine) (207) . Depending on whether the editing events occur in coding regions or 3 0 UTRs, ADAR-mediated editing of mRNAs can result in post-transcriptional protein coding mutations or altered susceptibility to microRNAs (208) . Recent data suggest that germline variation of ADAR genes may influence ovarian cancer susceptibility (209) . ADAR1 editase activity has been implicated in the oncogenic transformation of premalignant progenitors that harbor clonal self-renewal, survival, and cell cycle-altering mutations (210, 211) , such as in hepatocellular carcinoma precursors, where aberrant RNA editing of AZIN1 has been found to be a key oncogenic driver (210, 212) . Transgene expression of APOBEC-1 causes dysplasia and cancer in mouse and rabbit livers likely due to RNA editing of NAT1 (213). Study of ADAR1 regulation of APOBEC3 in neoplasia will be critical, potentially suppressing hypermutation and immunity (214) . Finally, inflammatory cytokine networks and JAK2/STAT signaling activate ADAR1 during relapse/progression in leukemia stem cell renewal, linking RNA editing to the development of innate immunity and potential preventive activity (215) .
Emerging data also suggest that some premalignant lesions may progress to cancer via fundamental epigenetic reprogramming. Indeed, reprogramming of the epigenome to a progenitorlike state may be required for driver mutations to induce tumorigenesis (216) . The role of BRAF mutations in benign nevi is a major historical conundrum (217) . In the BRAF V600E zebrafish model of melanoma, deletion of p53 promotes the nevus-tomelanoma transformation, but melanomas remain surprisingly infrequent considering that all of the cells bear both the oncogene and tumor suppressor loss (218) -a feature that replicates the phenomenon of "field defect" in human tumors. Two recent studies using preclinical models addressed this issue. Work with BRAF V600E/p53-null zebrafish now suggests that initiation of malignant transformation within such a "cancerized field" requires fundamental epigenetic reprogramming of these premalignant cells into an embryonic state via transcription factormediated reactivation of genes typically expressed only in neural crest progenitor cells (216) . This reprogramming involves binding of multiple transcription factors and generation of "superenhancer" regions. Engineered models, including epigenetic mechanistic studies, suggest key roles of p15 loss and autophagy (overcoming senescence) in promoting BRAF V600E-mutant transformation to melanoma (219) . Deletion of Atg7 inhibits tumorigenesis, likely via a mitochondrial mechanism (220) . Similarly, mouse model research recently demonstrated that basal cell carcinomas, known to be driven by oncogenic signaling in the hedgehog pathway, only originate from stem cells located in very specific areas of the murine epidermis, rather than from more committed progenitor cells (221) . Like the zebrafish model, this study provides evidence that the earliest stages of tumorigenesis are characterized by reprogramming to a more embryonic cell state. Such data suggest that tumor-initiating cells can be identified -and potentially targeted for early destruction -through their ability to reactivate an "embryonic" epigenetic state, highlighting one of the PCS's key missions: studying premalignant cells and model systems to better understand when epigenomic changes arise and how stable they are over time.
The Power of Immunology and Biochemistry to Facilitate Cancer Prevention

Immune oncology
The integration of multiple omics analysis platforms with immune-informatics analysis can be the foundation of a more effective framework for precision prevention (222) . There is now a wealth of evidence from both animal models and cancer patients of how the immune system can survey and recognize peptides encoded by certain genetic mutations when such peptides are presented on the surface of the cancer cell bound to MHC-Class I and Class II molecules. For example, RAS mutations, which are key oncogenic drivers in a wide array of cancers, may also be targets of immunosurveillance since T-cells specific to mutated RAS peptides have been found in cancer patients (223) and may be a viable target for immune approaches to treatment and even prevention (224) . Proof-of-principle studies of vaccine targeting mutant Kras (with Treg depletion) in a pancreas mouse model induced CD8
þ T-cells specific for the Kras mutation and showed preventive efficacy in the early PanIN setting (225) . In addition to predicted mutations in known oncogenes, cancer cells and their precursors can harbor tens to hundreds of random mutations throughout their genome. Vaccine-based approaches hold particular promise since they are a form of precision prevention with few side effects. Viral vaccines (e.g., to HPV) given before exposure can provide longterm protection from cancer development after only one or two treatments (5, 226) . HPV vaccines have modest activity, however, in treating chronic viral infections and related precancers, and far less activity in treating established cancers. The mechanisms of viral immune evasion vary by pathogen (seven viruses have been linked with human neoplasia), but are strikingly similar to those used by non-viral neoplasias, supporting the inclusion viral oncogenesis in this PCA (227) . For example, HLA genes have been linked to development of certain cancers. The minor MHC class I gene HLA-G plays a key role in immune evasion and HPV infection and transformation of CIN III to invasive cancer (228) . Evidence for immune surveillance has been reported in healthy people and associated with lowered lifetime cancer risk. Childhood febrile viral infections have been associated with reduced cancer risk, consistent with an influenza mouse model in which the virus infection elicited protective antibodies and T-cells specific for host and some tumor-associated antigens (229) . These data suggest that infection-induced immunity and immune memory could provide long-term immune surveillance of cancer, important properties for vaccine targets. T-cells are likely the main effector cells in preventing most forms of cancer. The immune system has the ability to recognize precancers and generate immune responses to potentially intercept and prevent cancer (51, 58, 230) and avoiding immune elimination is a hallmark of cancer (7, 231) . We must learn how to both strengthen T-cell immunity -either through immunization, drugs, or engineeringand concurrently overcome a dynamic hostile tumor microenvironment that prevents T-cell activation and infiltration into early neoplasia. The latter involves multiple factors, for example, metabolic reprogramming of the microenvironment by the high utilization of extracellular glucose and glutamine results in extracellular lactate, which attenuates dendritic and T-cell activation, stimulates macrophage polarization to an M2 state, induces VEGF secretion by stromal cells, and activates NF-kB. The microenvironment can in turn have profound effects on the metabolism of neoplastic cells (83) . Emerging data suggest that microenvironment barriers develop early in precursor lesions but are likely qualitatively different from more established cancer-associated barriers. The progressive accumulation of somatic changes that leads to neoplasia also co-opts neighboring vascular, neuronal, and other normal cells to support/promote oncogenesis.
Remarkable new data revealed that high-level arm-and wholechromosome-SCNAs drive immune evasion (232) . This unanticipated effect is in striking contrast mutational burden effects on immunity, and can override immune response even in high mutational/neoantigen burden settings (e.g., MSI-H/MMR-deficient tumors), revealing an increasingly complex interplay between SCNA levels, gene (including driver mutations), and immunity. Critical to vaccine development, therefore, is the identification of potent immune enhancers/adjuvants (e.g., metformin, STING) that can specifically target one or more innate pathways (233) and alter the developing inflammation that promotes immune suppression (234) . Experience with therapeutic cancer vaccines shows that targeting a single antigen or a single mutated peptide invariably leads to outgrowth of cancer cells that have lost that mutation. This may happen in the precancer setting as well, requiring a vaccine that elicits a polyclonal and polyspecific immune response. Trial endpoints could include T-cell receptor sequencing to look at clonality and clone expansion and potentially liquid biopsy detection of low levels of specific mutations or mutational load, SCNAs and imaging of the microenvironment, immune response (235), and high-grade precancer (e.g., PanIN-3) (56).
In a clinical feasibility trial of advanced adenoma patients, lack of immune response to a MUC1 cancer vaccine correlated with increased levels of circulating MDSCs responsible for inhibiting adaptive immunity (236) , suggesting that these may be useful biomarkers to identify individuals unlikely to benefit from preventive cancer vaccines. As above, research into drugs that could help overcome such immune resistance will be critical. Metformin, for example, has many key properties in this context and has been shown to enhance T-cell immunity and immune memory, and also influence the microbiome, by various mechanisms, including involving mitochondrial biology and RANK-L inhibition (see above) (41, (237) (238) (239) . Furthermore, prospective cohort data suggest that aspirin prevention of CRC is related to its effects on T-cell immunity (240) . Large study of adenomas reported a highly inflammatory microenvironment (241) , which varied by histology and location (242) . Two recent NGS studies of IBD (colitis)-associated CRC suggested that, compared to their sporadic counterparts, colitis-associated CRCs have a distinct mutational profile associated with cell-to-cell signaling, cell adhesion, and epigenetic regulators/chromatin modifiers, all linked to IBD inflammatory mediators (243, 244) . IDH1 mutation (extremely rare in sporadic CRC) was found only in Crohn's associated CRC. Future IBD NGS should include epigenomic and microbiome profiles and dysplasia.
Microbiota-immune interactions are an increasingly important and challenging field. Each human body contains at least 40 trillion microbial cells (microbiota), which have exponentially more genes (the microbiome) than do human cells; 99% of microbiota reside in the gut microbiome and certain bacteria can influence oncogenesis, inflammatory microenvironments, and immune interventions. Low-grade gut inflammation due to microbiota weakens epithelial tight junctions and may cause cancer risk factors -obesity and Type 2 diabetes (245). Intestinal barrier function (and bacterial translocation) is regulated by GWAS-identified laminin nuclear and mtDNA variants (19, 127, (246) (247) (248) and inflammatory cytokines such as IL-1B and IL-18 (249), autophagy (250) , and carbohydrates (which affect gut mucous layer and microbiota spatial organization) (251) . Thymic stromal lymphopoietin (TSLP) is a cytokine expressed mainly by epithelial cells at barrier surfaces (skin, gut, and lung). Short-course calcipotriol, a topical specific TSLP inducer FDA approved for psoriasis, durably suppressed skin cancer development in genetically engineered mouse models (GEMMs) consistent with an immune memory response, markedly reduced actinic keratosis (mediated T-cell adaptive immunity) in a randomized clinical trial (252) . In the Min mouse model, innate and adaptive sources of IL-17 promote pathologic myeloid inflammatory signature and colon tumorigenic response to enterotoxigenic Bacteroides fragilis (ETBF); and anti-IL-17 monoclonal antibody (mAb) and Treg cell depletion suppressed tumorigenesis at the micro-adenoma stage (23) . Emerging data suggest a link between ETBF, inflammatory bowel disease (IBD), and CRC. ETBF toxin-triggered colon tumorigenesis is characterized by a specific immune signature (combining IL-17-driven colitis and altered myeloid differentiation into MDSC) (253) . Potential other immune and/or microbiota prevention factors include lifestyle (97), antibiotics, diet, and microbial reprogramming (254, 255) . It has been shown that gut microbes modulate whole host immune and hormonal factors influencing the fate of distant precancers (e.g., breast), for example, by stimulating host immune cells to prevent dietary and genetic predisposition to mammary cancer in mice. This raises the possibility that the tumor microenvironment interacts with broader systemic microbial-immune networks (256) . Caloric restriction is the most consistently effective cancer preventive approach in virtually every mouse model/ tumor type tested. Recent data, including from the mutant Kras lung mouse model, indicate that caloric restriction or its mimetics (e.g., over-the counter hydroxycitrate) elicit autophagy, which improves immunosurveillance via Treg depletion and prevents malignant transformation (257) .
Analyses of NGS genomic data are critical to develop vaccines that target specific epitopes derived from mutations, copy number alterations, or other variants common to precancers. However, this direct strategy is especially challenging given the large number of alterations, low penetrance of driver mutations, so-called "long tail" problem (low frequency mutations) (258) , and corresponding mutant peptides, which do not lead to effective antigen presentation and response (259) . Mass spectrometry-based analysis and immunogenic assays in mice (260), coupled with precursor NGS genomic data, will help select better precancer vaccine targets. Computational methodologies using existing resources and databases that catalog potential antigens (261) and machinelearning classification approaches to predict peptide binding affinity to HLA I and II have also been developed (262, 263) . Computational studies of neoantigen-epitope prediction algorithms have shown that only a very small proportion of predicted neo-epitopes are actually presented on MHC class I as targets of endogenous T-cell responses (11, 264, 265) . Using the NGS genomic data from precancers could use two strategies to nominate candidate neoantigens: 1) mutation-calling algorithms to identify frequently occurring antigens and 2) for the low frequency events, utilize functional maps described above to identify complementary antigens that associate with oncogenic states (184) . These filtered lists of neoantigens could predict strong epitope candidates in silico using algorithms and analytic pipelines based on stabilized peptide p-MHC-I binding affinity (264, 266) . Novel approaches are being developed to identify neoantigens that elicit T-cell responses and could help prioritize peptide candidates for vaccination (267) . Leveraging the PCA to develop high-throughput approaches and improved predictive algorithms to identify (and quantify) immunogenicity of the precancer antigenic repertoire will be critical to identifying potential immunosurveillance and vaccine targets (268) (269) (270) .
As above, the MHC/HLA complex (located on 6p21) is critical to immune oncology and vaccine development. HLA loci are highly polymorphic and implicated in cancer risk by multiple studies in a variety of tumor types, including via search of the NHGRI GWAS catalog (228, 271) . Highlighting the importance of biochemical studies in this context, a recent analysis found somatic mutations that disrupt b-2 microglobulin (a component of the class I MHC complex, located on chromosome 15) proteinprotein interactions, with a striking enrichment for mutations at protein interfaces involving b-2 microglobulin's binding partners (272) . It has been shown that disruption of b-2 microglobulin can minimize immunogenicity of human embryonic stem cells (273) . It is conceivable that such mechanisms may be employed by precancers and cancers to escape immune surveillance (274, 275) .
Biochemistry: understanding the molecular basis of neoplasia
TCGA and related studies have demonstrated that a large number of genetic and epigenetic factors, such as chromatin modifiers and remodelers, are highly mutated in a large number of solid tumors and in hematologic malignancies (276) . Recurrent mutations in genes that encode regulators of chromatin structure and function highlight the central role that aberrant epigenetic regulation plays in the pathogenesis of these neoplasms. Deciphering the molecular mechanisms for how alterations in epigenetic modifiers, specifically histone and DNA methylases and demethylases, drive hematopoietic transformation could provide avenues for developing novel targeted epigenetic prevention for hematologic neoplasia and could also inform future studies in solid tumors. Many such protein complexesincluding the MLL family (191) , the polycomb complexes PRC1 and PRC2, which contain EZH2, ASXL1, and BAP1 (277) , and the SWI/SNF chromatin-remodeling complex (278) -contain genes that are frequently mutated in human cancers (276) , but were initially identified in simple model systems, such as Drosophila and yeast, emphasizing the importance of including studies of model organisms in any large-scale efforts in cancer prevention. While genomic deletions and nonsense, frameshift, and splice site mutations that introduce a premature stop codon or alter protein structure can be obvious loss-of-function events, missense mutations can be hard to classify unless they alter enzymatic function or disrupt protein-protein interfaces within large functional protein complexes.
For example, a large number of hematologic malignancies harbor translocations of the N-terminal region of MLL1 to diverse fusion partners that share very little sequence or functional similarity. To understand how these diverse MLL translocations result in leukemogenesis, biochemical and enzymological studies (279) . Second, AFF4, itself a fusion partner of MLL in leukemia, has been found to be a common factor among all purified MLL translocations (280) . Third, ELL, one of the frequent translocation partners of MLL in leukemia, has been found to function as an RNA Pol II elongation factor that increased the catalytic rate of transcription elongation by RNA Pol II by suppressing transient pausing (281) . Finally, it has been shown that many MLL translocation partners are found in association with ELL and the positive transcription elongation factor (P-TEFb), within a complex named the Super Elongation Complex (SEC) (278, 282, 283) . The translocation of MLL into SEC is involved in the misrecruitment of SEC to MLL target genes, perturbing transcription elongation checkpoints at these loci and resulting in leukemia (283) . MLL-induced leukemogenesis highlights the role of deregulated histone methylation in tumorigenesis (284) . Another example of the importance of biochemistry is deciphering the molecular role of an observed genetic link of EZH2 in cancer. EZH2 encodes the catalytic subunit of the polycomb repressive complex 2 (PRC2), which is responsible for methylating lysine 27 of histone 3 (H3K27). Trimethylation at this site is associated with closed chromatin and silencing of neighboring gene expression. In neoplasia, EZH2 can influence T-cell biology (285) and function as either an oncogene or a tumor suppressor gene depending on the cellular context, for example, EZH is sufficient to transform lung cells in transgenic mouse models overexpressing EZH (286) , and loss-of-function EZH2 mutations occur in MDS and chronic myelomonocytic leukemia (CMML) (287) . In germinal center diffuse large B-cell lymphomas, recurrent mutations essentially of only one codon (Y641) create a protein with reduced affinity for unmethylated H3K27 but highly increased affinity for monomethylated H3K27, resulting in higher levels of H3K27 trimethylation overall. In contrast, pre-AML syndromes like MDS and CMML do not develop Y641 mutations but instead recurrently develop nonsense, frameshift, and other loss-of-function mutations in EZH2 resulting in low levels of H3K27 trimethylation (288) . Ezh2 loss synergizes with JAK2-V617F in hematopoietic cells to contribute to the development and progression of MPN. The MPN phenotype induced by JAK2-V617F was accentuated in JAK2-V617F;Ezh2(À/À) mice, resulting in expansion of the stem cell and progenitor cell compartments and severe disease progression, including more advanced myelofibrosis and reduced survival (289) . These results, which support tumor suppressor function of EZH2 in patients with MPN, have important clinical implications for EZH2 inhibitor development in this setting. It is possible that EZH2 inhibition will mimic malignancy-associated, loss-of-function EZH2 mutations in normal myeloid cells leading to dysregulated growth or differentiation in these cells, highlighting the need for future contextdependent studies.
SWI/SNF, also known as the BAF complex, is also a critical regulator of nucleosome remodeling conserved from yeast to humans. Biochemical investigation combined with bioinformatic assessments have demonstrated widespread genomic alterations that occur across the members of the complex in 19.6% of all human tumors reported in 44 studies (290) . In synovial sarcoma, SS18-SSX oncogenic fusion that results from a fusion of 78 amino acids of SSX to the SS18 subunit of BAF complex was shown to disrupt binding of BAF47, tumor-suppressive member of the complex, leading to reversible dysregulated growth (291) . In liver, genetic suppression of SWI/SNF complex member ARID1B was shown to overcome oncogene-induced senescence and lead to liver neoplastic progression (292) . While these studies suggest an emerging role for SWI/SNF in tumorigenesis, better delineating the role of SWI/SNF complexes in precancers will also be important. Furthermore, prior studies demonstrate antagonistic relationship between the SWI/SNF and PRC2 complex in mediating oncogenic transformation (293) .
A transformative example of biochemistry's importance in premalignant biology involves the discovery of recurrent mutations in IDH1 and IDH2 in glioblastoma, AML, and their precursor cells. Such mutations were found through broad sequencing efforts (294) although their role at the molecular level was not clear until the advent of modern metabolomics profiling (295) , which found that mutant IDH enzymes convert the normal intracellular metabolite alpha-ketoglutarate into 2-hydroxyglutarate. A competitive inhibitor of a large class of dioxygenase enzymes that utilize alpha-ketoglutarate, 2-hydroxyglutarate accumulates to very high levels in IDH-mutated cancers, potently inhibiting many important intracellular dioxygenases, including the TET family, prolyl hydroxylases, and several histone demethylases (296) (297) (298) . Thus, biochemistry and metabolomics have illustrated how 2-hydroxyglutarate contributes to carcinogenesis in a hitherto unprecedented way by acting as a novel "oncometabolite" generated by somatic IDH1/IDH2 mutations that can potentially serve as targets for both cancer prevention and therapy, including vaccines (299) .
Biochemical approaches have also focused on the significance of metabolism and its link to epigenetic factors, such as the TET family in the regulation of cell-lineage specification and the development of cancer (191) . These discoveries are only a few examples among a large number of biochemical approaches in neoplastic cancer studies and are the testimony to the power of biochemistry in understanding neoplasia and the design of its targeted prevention, for example, by highlighting the importance of epigenetic regulation. High information content mass spectrometry to profile global histone modifications in human cancers (300), when combined with the DNA-sequencing data, can be used to identify novel variants that can drive epigenetic changes that can lead to oncogenic transformation. Chromatin-immunoprecipitation technology combined with NGS sequencing (ChIPseq) can provide systematic information regarding the architecture of the chromatin cell states of cancers. New technological advances have demonstrated that CHIP-seq can be carried out in human tissues including tumors (301) . Interestingly, examination of the chromatin landscape was able to fully distinguish normal versus cancer samples. These results suggest the possibility of gaining additional insights into precancers by systematic assessment of chromatin states using key histone acetylation and methylation patterns, super-enhancers, as well as TET, SWI/SNF, and PRC2 complex, all of which are critical for chromatin regulation (301) .
It is essential that the PCA incorporate detailed biochemical and enzymological studies on purified protein complexes to decipher the precise, context-dependent function of chromatin and other epigenetic modifiers and somatic mutations in precancer development and progression (280) . This will also allow the profiles to be cross-referenced with the landscapes in primary tumors, as well as of the corresponding transcriptomic data to identify critical epigenetic changes that are necessary for malignant transformation. The context-dependent, complex roles of EZH2 mutations and PRC2 and SWI/SNF complexes in chromatin regulation in normal development and neoplasia require further study, especially in precancers. Finally, metabolic alterations in neoplasia continue to uncover novel connections between nutrient utilization and oncogenic state, critical to precancer progression.
Single-Cell Analyses
The natural history of precancers is heavily influenced by the heterogeneity (including genetic and epigenetic (302) of neoplastic cells and tissue microenvironment. Single-cell RNA-or DNA-sequencing technologies can be specifically leveraged to unravel the complex cellular relationships within these lesions that cannot be addressed by assaying bulk tissue (303, 304) . In the case of mRNA profiles, downstream analyses can characterize known populations and novel subpopulations of cells and assess how these populations change in abundance as disease progresses or regresses. These data also can be used to more accurately infer important disease-associated gene regulatory and immune cell networks (305) because the gene expression variability has not been averaged across all sampled cells as in bulk tissue. In addition, single-cell sequencing can reveal and monitor lesion heterogeneity in somatic alterations and dissect complex clonal dynamics among epithelial cells sampled at different geographic locations and over time to complement existing multiregion bulk sequencing approaches (306) . These data will provide a high-resolution picture of cell types present in precancers and their surrounding microenvironment and the transcriptional programs active within each cell type that drive disease progression.
However, several technical limitations need to be overcome to realize the full potential of single-cell sequencing of precancers. These lesions are relatively small and frequently only diagnosed in formalin-fixed, paraffin-embedded (FFPE) tissues previously precluding comprehensive genome-sequencing studies using current methods (307) . Furthermore, information regarding the location of neoplastic cells with particular mutations within a given lesion is especially important for early lesions, as this often defines the boundary between preinvasive and invasive neoplasia. Therefore, the development and application of methods that allow assessing the genetic and phenotypic features in situ using intact FFPE tissue samples is especially critical for the improved understanding of preinvasive lesions. Several technologies enable copy number alteration and gene expression analyses at the single-cell level from FFPE slides. These include FISH and immuno-FISH (combination of FISH with immunofluorescence; refs. 308, 309), mRNA in situ hybridization, in situ PCR, and STAR-FISH (310) (311) (312) . The application of immuno-FISH for the analysis of cellular phenotypic heterogeneity and genetic features revealed extensive intratumor diversity in DCIS and clear expansion of minor subclones in DCIS to dominant clones in invasive ductal carcinoma (309) . A shortcoming of these methods is the limited set of markers that can be assessed on a single slide and the need for a priori knowledge of the changes to be analyzed.
Single-cell methods are beginning to be applied to premalignancy, including sequencing on both fresh/frozen and FFPE has been applied to an epithelial precancer site, DCIS, and associated invasive breast cancers, and included massively parallel single-cell sequencing for copy number analysis (180) . This proof-of-principle analysis established technical feasibility and demonstrated intralesion genetic heterogeneity at DCIS, suggesting complex and distinct evolutionary processes involved in early DCIS to subclonal selection in invasive disease. Multicolor FISH to study clonal evolution at single-cell resolution in Barrett's esophagus found extensive genetic diversity in progressors (313) . A whole-exome single-cell sequencing method was developed to assess genetic heterogeneity and tested on a premalignant JAK2-negative myeloproliferative neoplasm (essential thrombocythemia) patient (314) . Such profiling of a different myeloproliferative neoplasm myelofibrosis revealed substantial heterogeneity in cytokine production (315) . Recent single-cell genomic study of childhood ALL provided a highresolution view of the preleukemic sequence of events leading to ALL, including early ETV6-RUNX1 translocations in hematopoietic precursors to later APOBEC-mediated transformation to leukemia (316) . Importantly, however, current single-cell sequencing approaches have important technological limitations, especially in epithelial precancers. First, the methods available are labor and cost intensive. Second, it is currently not possible to obtain accurate detailed copy number and mutational data from the same cell, given that some wholegenome amplification methods yield templates optimal for copy number analysis, whereas others are optimal for mutation profiling. Therefore, efforts are required for the development of less labor-intensive and more cost-effective methods for sequencing approaches and clonal lineage tracing, which are essential for a detailed analysis of the evolutionary paths of in situ disease and its progression to invasive cancer. Two more technologies, FISSEQ (fluorescent in situ sequencing; ref. 304) and "spatial transcriptomics" (317), allow for complete transcriptome analysis of single cells in intact tissue sections. Recently, single-cell techniques have been developed to study chromatin maps/signatures and epigenetic heterogeneity in neoplasia (318, 319) and the microbiome (320), including imaging of host-microbiota interchanges (251, 321) .
Cost reduction and advances in cell sequencing (and cfDNA technology) could theoretically allow temporal monitoring of blood and epithelial premalignancies on a population scale within the PCA (322) (323) (324) . Periodic single-cell DNA sequencing of multiple cells from an individual will be invaluable for cancer prevention as it will allow one to assess the overall baseline accumulation of somatic mutations over time in a person, to survey and monitor multiple different endogenous processes and exogenous exposures through the use of mutational signatures, and to reveal the existence of premalignant clones and clonal evolution over time (325) (326) (327) . The unprecedented resolution of sequencing single cells comes with a hefty computational and data price. Monitoring even a single individual will require multiple sequencing of one's genome every year resulting in several terabytes of data per person. As such, population-scale examinations will generate millions of whole-genome sequences resulting in exabyte scale data (>10 18 bytes) requiring next generation of computational infrastructure (328) and novel computational frameworks (e.g., to take into account their relatively low signal resolution when compared with traditional bulk tissue sequencing). Challenges for whole-genome analyses with single-cell resolution will be highly amplified with multi-omic sequencing (329) . More than ever, the rate-limiting step will be data analysis. 
Liquid Biopsies for Early Detection and Intervention
By virtue of the clonal nature of tumor cells, somatic changes are present in many copies that are continuously released and can be detected in the blood as cell-free (cf) circulating tumor DNA (330) . In cancer patients, alterations in cfDNA can be detected using sequencing and bioinformatic approaches, although such alterations can be difficult to detect as they often represent a minute fraction (<1%) of cfDNA. A variety of both targeted and whole-genome approaches have been developed to detect such alterations in cfDNA (331, 332) . These have been used for early detection of recurrence in colorectal cancer, pancreatic cancer, neuroblastoma, hematopoietic malignancies, and others (333) (334) (335) . Importantly, cfDNA detection of pancreatic cancer recurrence appears to precede radiographic detection of recurrence by over six months in some cases, providing a larger window for potential intervention in this challenging disease (334) . A new phylogenetic multiplex-PCR NGS platform approach to ctDNA profiling provides sufficient sensitivity to both identify lung cancer patients destined to relapse within a year subclonal detection. Of importance to early detection research, cfDNA was recently detected in plasma in patients with premalignant lung and bladder disease (336, 337) . Differentially methylated loci in multiple HPV and host genes were detected by NGS in urine cfDNA could lead to precision screening in cervical premalignancy (338) . Somatic mutations in cfDNA among individuals without any precancer diagnosis, however, pose even more serious challenges for the development of ctDNA screening tests (339) .
Achieving acceptable levels of sensitivity and specificity for early cancer detection will require further technical advances to identify possible combinations of cancer-specific mutations and define potential quantitative thresholds to avoid overdiagnosis. Enrichment steps can be based on biological properties (e.g., surface expression markers) or physics (e.g., size, density, deformability). Based on findings to date, it can already be envisaged that DNA sequencing needs to be broad, to encompass considerable tumor heterogeneity, and deep, to detect minute amounts of ctDNA fragments in the milieu of extensive genetically normal cfDNA. Nonmalignant conditions that can lead to the death of normal cells may also lead to a further dilution of ctDNA molecules and hamper quantitative evaluations. Very sensitive technologies that allow the detection of less than 0.1% of ctDNA in blood plasma (e.g., digital droplet PCR or cancer personalized profiling [CAPP] by deep sequencing methods) have been developed and applied to cfDNA analyses in patients with various forms of cancer (340) , but the key biological limitation might be the number of genome equivalents present in blood samples from early-stage cancer patients (341) .
Much work remains to be done in improving methodologies for detection of circulating tumor DNA. In addition to the need for higher sensitivity, the specificity of cfDNA measurements also faces serious challenges. Several emerging reports have shown that cancer-associated mutations are not restricted to cancer patients. For example, very low levels of TP53-mutated cfDNA were observed in plasma of 11.4% of 123 matched noncancer controls (339) and in the peritoneal fluid and peripheral blood of women with benign ovarian lesions (327) . Likewise, a potential confounding issue is the detection of clonal alterations that arise in blood cells of healthy individuals that may be associated with aging and clonal hematopoiesis (see below). Distinguishing between alterations in genes associated with MDS/AML versus solid tumors may be one way to overcome this issue. Additionally, even when molecular alterations are identified, determining the tissue of origin of the incipient neoplastic lesion can be extremely difficult and complex. Combining sequencing of cfDNA with epigenetics markers (342, 343) , mutational signatures, imaging and mathematical modeling can be used for pinpointing the most likely tissue in which the clone originated. Even greater issues challenge the promise of ctDNA analysis for early cancer detection. Genomic alterations, such as those in the BRAF, RAS, EGFR, HER2, FGFR3, PIK3CA, TP53, CDKN2A, and NF1/2 genes, all considered hallmark drivers of specific cancers, can also be identified in benign and premalignant conditions, occasionally at frequencies higher than in their malignant counterparts (214) .
Analysis of other blood/fluid components, such as exosomes, platelets (344) , urine, peritoneal fluid, and circulating tumor cells (CTCs), may help increase the sensitivity of detection (330, (336) (337) (338) . CTCs are released early during tumor development (330) and have been found in patients with small primary tumors. Thus, detection of CTCs might be an alternative approach to early cancer identification. Circulating tumor cells have been detected in 3% of patients with chronic obstructive pulmonary disease (COPD) who have an elevated risk of developing lung cancer 1-4 years before annual CT-screening detected lung nodules (345) , possibly complementing a CLIAapproved bronchial airway genomic classifier (FDA Laboratory Developed Test [LDT]) validated for lung cancer detection (346) , but were not detected in control individuals (both smokers and nonsmokers) with normal lung function. Technical advances have established the feasibility of detecting and NGS of CTCs collected from blood at the very early steps of tumor invasion (347) .
Focusing on population groups at an elevated risk of developing cancer (e.g., COPD patients or individuals with inherited cancer susceptibility) is a good strategy to speed up the process of testing and validation of emerging approaches and technologies before considering large population-based screening efforts as indicated above. CTCs have been detected in $10% of CRC precancers (adenomas) possibly stimulated by cytokinedriven epithelial migration (348) . Enormous resources are required to identify genomic aberrations specific and sensitive enough to detect early malignant lesions in large cohort studies. Finally, verification of the findings of approaches involving liquid biopsy will call for acquisition of information on the putative location of the occult lesion to select the appropriate imaging modalities or other diagnostic means prior to planning appropriate therapies. In this context, tissue-specific multiplex transcriptome profiling of single CTCs (349) might be a promising approach. With these approaches, it is possible to imagine a time when individuals at high risk of developing cancer due to either genetic or environmental risk factors could be serially monitored using a blood-based test. A potential advantage of this approach would be the relative ease of compliance compared with other more invasive screening technologies. Ultimately, the specific methodology would be determined by practical considerations such as cost, sensitivity, specificity, and robustness of the assays, but these approaches may forever change screening for cancers that are currently incurable unless diagnosed at an early stage.
Longitudinal Analysis of Premalignancies
It is likely that synchronous precancer/cancer pair studies will not always accurately reflect the temporal clonal evolution underlying neoplastic transformation, i.e., genetic alterations found in precancer adjacent to cancer are not comparable to those found in precancer in a patient who never progressed (as well shown in Barrett's esophagus). To fully appreciate such mechanisms, systematic longitudinal analyses of malignant cells will be essential.
To date, such analyses of epithelial premalignancies, with the exception of Barrett's esophagus, have been extremely limited, with reports of a relatively small number of patients with squamous lung premalignancy (350, 351) . DNA-and RNA-seq of these lesions have identified molecular alterations in both epithelial cell signaling pathways and immune cell pathways that associate with progression of these premalignant lesions over time. Surprising relationships between SCNA types and levels, mutation burden (including cancer drivers), cell cycle markers, and immunity have major implications on malignant transformation. Large longitudinal studies of Barrett's esophagus established SCNAs as essential oncogenic drivers (352, 353) . Nonprogressors largely maintained stable genomes, in contrast to patients with high levels of SCNAs, genome doubling, genetic diversity, and chromosomal instability/catastrophe associated with rapid (<2 years) progression to esophageal cancer (232, 353) .
Another recent Barrett's study of clonal evolution at single-cell resolution using multicolor FISH found that baseline genetic diversity predicts progression (to cancer) and remains in stable dynamic equilibrium over time, suggesting that clonal make up and evolutionary trajectory of the lesion is predetermined from the outset (313) . Clonal expansions were rare, often involving p16. Importantly, this work has established the feasibility and model of longitudinal study in epithelial premalignancy.
Focusing on premalignancies of the blood has several advantages, including the ease of repeatedly acquiring neoplastic cells to study their clonal evolution, discoveries that inform single-cell sequencing studies in epithelial neoplasia. For example, study of myeloproliferative syndromes (201) provides the only direct data that somatic mutation order (JAK2 and TET2) can greatly influence disease features. The overall malignant transformation rate for clonal hematopoiesis, monoclonal B-cell lymphocytosis (MBL), and monoclonal gammopathy of undetermined significance (MGUS) is about 1%-2% per year, but individual risk is highly variable. Comprehensive single-cell and cfDNA omics studies will play a key role in improving our understanding of disease pathogenesis. We now have the ability to monitor hundreds of individual cells, thus overcoming bulk-cell/tissue limitations and allowing precise study of intraclonal and microenvironment architecture and crosstalk in the process and timing of transformation. The complexity and importance of follow-up is highlighted by findings in pancreas precancers, which can exhibit significant clonal heterogeneity/diversity that surprisingly decreases during transformation (354) .
Clonal hematopoiesis was initially discovered (355, 356) by NGS identification of somatic mutations in genes (mutant clones of mostly single driver mutations) similar to the mutational spectrum seen in MDS (notably DNMT3A, JAK2, TET2, and ASXL1) that increased markedly with age in the general population (357, 358) . Although the mechanism is unclear, most people with clonal hematopoiesis of indeterminate potential (CHIP) can stably harbor small hematopoietic clones for long periods of time. These clones must have initially expanded to the point of being detectable but then were held in check (358) . One possibility is that the somatically mutated clones are able to persist in a finite number of pseudo-niches not available to normal stem cells. Once these pseudo-niches are filled, the clone cannot expand further until additional mutations are acquired or the microenvironment is altered to create additional area hospitable to these cells. This is analogous to why BRAF-mutant moles only grow so much before they become stable, until epigenetic reprogramming or some other event promotes transformation (see epigenetic section). Recent studies have demonstrated how cells with a wide range of somatic mutations typical of myeloid malignancies (e.g., in U2AF1, SF3B1, SRSF2, ASXL1, or TET2) can induce inflammatory conditions and innate immune responses that then favor the growth of these mutant cells. Drugs targeting the inflammasome and innate immune responses implicated in remodeling of the microenvironment are potential preventive approaches under investigation (359, 360) .
Whether adaptive immune surveillance plays a role in limiting the expansion of pre-malignant clones is less clear. However, T-cell mediated autoimmunity is well documented in some forms of MDS and downregulation of MHC-II is common suggesting that interactions with the adaptive immune system likely play a role in the development of these myeloid malignancies. It appears that the aging bone marrow microenvironment promotes outgrowth of clones driven by mutations in splicing factor genes (e.g. SF3B1, SRSF2) and is associated with innate and adaptive immune attrition (361) . Murine findings suggest that aberrant splicing may also produce neoantigens, capable of eliciting an immune response that would need to be suppressed or evaded for progression to occur. Aplastic anemia is a slightly different scenario, with two distinct processes occurring -immune mediated destruction of hematopoietic cells and a constant stimulus for the regeneration of these cells. Two kinds of clonal hematopoietic cells may be selected for in that environment -those that can evade the immune system (reverting to a more normal stem cell state) and those that acquire mutations promoting clonal expansion. Clonal hematopoiesis is highly prevalent among patients with aplastic anemia (À50%), in which two broad types of genetic alterations are identified: (1) age-related mutations and CNAs commonly seen in myeloid malignancies (e.g., DNMT3A, RUNX1, ASXL1) and (2) those not age related and highly specific to aplastic anemia -PIGA and BCOR/BCORL1 mutations and uniparental disomy (UPD) in 6p (6pUPD) identified SNP array karyotyping, which in contrast to the first type, is associated with stable or decreasing clone size over time and much lower rates progression to MDS/AML (362) . 6pUPD functionally results in deletion of half of the class I HLA locus, providing a mechanism for evasion of an immune response. Outside of this context, this event would not be predicted to confer a clonal advantage. In aplastic anemia, this form of immune evasion would allow stem cells to function as they might were the immune response not present. Clones with driver mutations in MDS-related genes, on the other hand, may gain proliferative or niche-independent growth capabilities that are more oncogenic. This is born out by observations that 6pUPD is more common in children with aplastic anemia, an age-group where CHIP mutations are rare and that 6pUPD is exceedingly rare in elderly MDS and AML. This suggests that 6pUPD is not an oncogenic event but only allows stem cells to persist in the setting of autoimmunity. Nearly 40% of clonal hematopoiesis individuals with unexplained cytopenias harbor detectable mutations (200, 358) , many with clones having more than one driver mutation and higher risk of transformation to MDS/AML and all-cause mortality (200, 358, 363) . Cooperating mutations also can be identified during periods of clonally skewed hematopoiesis in sporadic and hereditary settings that precede myeloid transformation. DNMT3A haploinsufficiency transformed FLTmutant myeloproliferative disease into AML in mouse model (364) . The frequent co-occurrence of germline GATA2 and somatic ASXL1 events (365) and germline SNPs associated with somatic mutations of JAK2 have uncovered several targetable cooperative mutations (366) driving premalignant progression (367) . Examples of hereditary mutated transcription factors that predispose to hematologic neoplasia include mutations in CEBPA, RUNX1, ETV6, and PAX5 (367). A recent GWAS identified germline variants that predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms (366) . Four genes (JAK2, SH2B3, CHEK2, and TET2) altered in both inherited and somatic settings, contribute to V617F clonal hematopoeisis and/or MPN development. This study's identification of a predisposition allele associated with TET2 is intriguing since somatic TET2 mutations are common early events in myeloid precursors, including clonal hematopoiesis and myeloproliferative neoplasms, and can be identified in hematopoietic stem cells, either preceding or following the acquisition of V617F, and the mutational order of these two genes can influence the clinical and biologic behavior of these neoplasms (201) .
MBL is an asymptomatic expansion of clonal B cells in the peripheral blood present in roughly 4% of all U.S. individuals over the age of 40 years (368) . Genetic predisposition to MBL is suggested by the finding that the incidence of MBL is 3-fold higher for individuals within familial chronic lymphocytic leukemia (CLL) kindreds (defined as families with at least two first-degree relatives with CLL). A large GWAS of CLL families (including 60 relatives with MBLs) found significant germline variant associations in two out of eight regions tested (369) . NGS has shown that most mutations and intraclonal heterogeneity found in CLL are already present in MBL years before progression (370, 371) . Furthermore, longitudinal MBL studies, including those from patients who progressed to CLL, have begun to elucidate the sequence, timing, and impact of subclonal expansion and T-cell exhaustion on malignant transformation (369, (372) (373) (374) . Risks of serious bacterial infections in individuals with MBL are similar to those with CLL (375-377) and linked to MBL transformation (378, 379) and solid tumor risk is 3-to 4-fold higher in MBL and CLL (versus healthy controls), all thought to be due to defects in immune surveillance (376, 377) . Antibody responses to primary and secondary antigen challenges are typically inefficient among patients with early-stage CLL. Preliminary data have shown that immunologic T-cell synapse is defective in individuals with MBL as well (368) . Efforts to generate efficient vaccine responses will, therefore, be challenging. Enhancement of cytolytic T-cell function in MBL via vaccine therapy should be a longterm challenge as graft-versus-leukemia is highly effective in eradicating leukemic B-cells. Both in vitro and in vivo data suggest that lenalidomide can repair defects in the T-cell immune synapse and reduce Tregs in CLL patients (380, 381) , an approach currently being tested clinically in MBL. Of note, new mouse model data suggest that age and inflammatory status of the host microenvironment promotes selection for adaptive oncogenic events in B-cell progenitors (382), analogous to clonal hematopoesis. Related work involves a hereditary syndrome of susceptibility to pre-B-cell neoplasia caused by inherited mutations of PAX5. Recent mechanistic data indicated that inherited susceptibility and aberrant immune responses to postnatal infections drives B-cell clonal evolution of premalignant B-cells and transformation to leukemia and lymphoma, by showing that pre-B-ALL was initiated in Pax5 heterozygous mice only when exposed to common infections (383) .
Studies of MGUS have provided some of the best evidence that the immune system has the capacity to recognize precursor states (384) . Search for shared targets of immune response led to the finding that T cells against stemness antigens (such as SOX2) are particularly enriched in MGUS (versus MM; ref. 385 ). Prospective data demonstrate that SOX2 immunity correlates with risk of transformation (230) . Prevention strategies include boosting preexisting T-cell immunity, for example, with SOX2 vaccines and immune-modulatory drugs (386) . NGS has highlighted clonal evolution and heterogeneity in longitudinal studies (387, 388) . Similar to clonal hematopoiesis above, MGUS cells demonstrate clinical dormancy despite NGS suggesting that the majority of genomic alterations found in MM are found in precursor gammopathies (387, 388) . Interestingly, new humanized models developed to grow precursor cells in vivo indicate that MGUS cells have the capacity for progressive growth, suggesting that the clinical stability/dormancy of these cells is in part mediated by features extrinsic to tumor cells, such as the immune system or bone marrow niche, where signals derived from osteoblasts may be important for mediating dormancy of MGUS cells (389) . These humanized models to grow premalignant cells in vivo should greatly advance the study of clonal evolution and malignant transformation in this setting (390) . Inherited genetic variation in specific SNPs increases MGUS predisposition and risk of transforming to MM (391) . Loci identified also points to a role for chronic antigen-driven stimulation in driving clonal origins and evolution in MM and other B-cell tumors. The risk of MM is particularly increased in some populations such as those with inherited lipid storage disorders, such as germline GBA mutations in Gaucher disease (GD), due in part to lysolipid-induced chronic inflammation and genomic instability. GD mouse models, for example, lysolipid substrate reduction in Gba1-deficient mice decreased the risk of gammopathies, studies already show marked preventive efficacy of targeting the underlying trigger of genomic instability (392, 393) . This led to the recent discovery that in nearly 25% of all cases of MGUS/MM, the underlying clone may be driven by lipid antigens such as inflammation-associated bioactive lipids (392) . Studies to characterize the precise nature of microbial/dietary/endogenous lipid antigens in the setting of lipid-reactive gammopathy will facilitate targeted prevention with pharmacologic/lifestyle changes.
Summary
While a number of interventions are already FDA approved for cancer prevention (detailed in ref. 394) , this is only the tip of the iceberg. New precision prevention approaches will be needed, including novel trial designs (e.g., involving molecular selection; refs. 395, 396) and agents (e.g., denosumab for BRCA1 carriers; ref. 37) (398) . Analogous to clonal hematopoiesis, albeit in much smaller numbers of individuals studied to date, ultra-deep NGS of somatic cancer mutations reported a distinct mutational profile (mostly NOTCH1) in normal skin (161) , potentially MBL (382), and liquid-biopsy technology is detecting very low levels of TP53-mutated cfDNA were observed in plasma of matched non-cancer controls (339) and in peritoneal fluid and peripheral blood from women with benign ovarian lesions (399), likely representing a premalignant mutational background events that accumulates in cancer and aging. Similar to BRAF-mutant moles, CHIP clones seem to expand to the point of being detectable but then are held in check (358) , until an epigenetic, immune, or other transforming event. The aging bone marrow microenvironment promotes clonal outgrowth driven by splicing factor mutations with innate and adaptive immune attrition (361) . Somatic myeloid mutations can induce inflammation and innate immunity favoring clonal growth. T-cell immunity and downregulation of MHC-II in MDS suggests a role for adaptive immunity in myeloid dysplasia. Probing germline (rare mutations and common variants)-somatic interactions is leading to novel prevention targets (61, 65) . Singlecell tools/approaches are beginning to reveal immense heterogeneity of certain precancers and are needed to dissect the detailed interactions of precancer cells with immune cells, and other components of the tumor microenvironment. Establishing a PCA that integrates multi-omics and immunity (Figure 1 ) will be critical to better interrogate and disrupt the disabling immunosuppressive properties in the tumor microenvironment and to identify immunogenic antigens to design vaccines to activate/ reprogram the immune response to detect, prevent, and reject precancers.
As indicated in this Perspective, the complexities of this project are daunting, but the disruptive tools to make the PCA feasible are coming on line and the potential public health benefits of preventing cancer are immeasurable. To accelerate the prevention of cancer, this field needs a large-scale, longitudinal effort, leveraging major initiatives and infrastructure, diverse disciplines, technologies, and models (e.g., involving stem/progenitor cells) (400) (401) (402) to develop a multi-omics and immunity PCA. This unified Atlas will provide a vast national resource for discovery to interrogate, target, and intercept events that drive oncogenesis.
In summary, to fully achieve cancer prevention, we must build teams with multiple areas of expertise from the NIH, academia, FDA, private foundations, philanthropic partners, and industry. The best analogy of assembling such a multidisciplinary team is the Manhattan Project-one goal, multiple experts.
Disclosure of Potential Conflicts of Interest
A.E. Spira reports receiving a commercial research grant from Janssen Pharmaceuticals and is a consultant/advisory board member for Janssen Pharmaceuticals and Veracyte Inc. M.B. Yurgelun reports receiving a commercial research grant from Myriad Genetic Laboratories, Inc. R. Bejar is a consultant/advisory board member for Genoptix, Celgene, Foundation Medicine, and Alexion. J.E. Garber reports receiving other commercial research support from Novartis and Ambry Genetics and is a consultant/ advisory board member for Biogen, Novartis, and GTx. V.E. Velculescu has ownership interest (including patents) in Personal Genome Diagnostics and is a consultant/advisory board member for Personal Genome Diagnostics. M.L. Disis reports receiving a commercial research grant from VentiRx, Celgene, Jannsen, Seattle Genetics, and EMD Sorono and has ownership interest (including patents) in VentiRx and Epithany. No potential conflicts of interest were disclosed by the other authors.
